[en] Microbial drug resistance is a growing problem of global magnitude. In gram-negative pathogens, the most important resistance problems are encountered in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter, with increasing trends observed for all major anti-gram-negative agents (β-lactams, fluoroquinolones and aminoglycosides). A matter of major concern is the emergence of new β-lactamases capable of degrading the expanded-spectrum cephalosporins and/or carbapenems, such as the extended-spectrum β-lactamases (ESBLs) and the carbapenemases. These β-lactamase genes are often associated with resistance determinants to non-β-lactam agents (e. g. aminoglycosides and fluoroquinolones), and strains producing ESBLs or carbapenemases often exhibit complex multidrug resistant phenotypes and sometimes are panresistant. The problem is worsened by the dearth of new agents active on multidrug-resistant Gram-negatives in the pipeline. The importance to develop better strategies to control resistance is underscored.
Disciplines :
Microbiology
Author, co-author :
Rossolini, G. M.; Department of Molecular Biology, Section of Microbiology, University of Siena, Italy, Dipartimento di Biologia Molecolare, Sezione di Microbiologia, Policlinico le Scotte, 53100 Siena, Italy
Mantengoli, E.; Department of Molecular Biology, Section of Microbiology, University of Siena, Italy
Docquier, Jean-Denis ; Université de Liège - ULiège > Département des sciences de la vie > Centre d'ingénierie des protéines
Musmanno, R. A.; Department of Molecular Biology, Section of Microbiology, University of Siena, Italy
Coratza, G.; Department of Molecular Biology, Section of Microbiology, University of Siena, Italy
Language :
English
Title :
Epidemiology of infections caused by multiresistant Gram-negatives: ESBLs, MBLs, panresistant strains
ALVAREZ, M., TRAN, J.H., CHOW, N., JACOBY, G.A. (2004). Epidemiology of conjugative plasmid-mediated AmpC β-lactamases in the United States. Antimicrob Agents Chemother. 48 (2), 533-537.
BERGOGNE-BEREZIN, E., TOWNER, K.J. (1996). Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 9 (2), 148-165.
BONOMO, R.A., SZABO, D. (2006). Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 43 (Suppl 2), 49-56.
BRADFORD, P.A. (2001). Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 14 (4), 933-951.
CORBELLA, X., MONTERO, A., PUJOL, M., DOMINGUEZ, M.A., AYATS, J., ARGERICH, M.J., GARRIGOSA, F., ARIZA, J., GUDIOL, F. (2000). Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol. 38 (11), 4086-4095.
COSGROVE, S.E. (2006). The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 42 (Suppl. 2), 82-89.
DESHPANDE, L.M., RHOMBERG, P.R., SADER, H.S., JONES, R.N. (2006). Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis. 56 (4), 367-372.
ENDIMIANI, A., LUZZARO, F., PERILLI, M., LOMBARDI, G., COLI, A., TAMBURINI, A., AMICOSANTE, G., TONIOLO, A. (2004). Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis. 38 (2), 243-251.
EUROPEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE SYSTEM. (2006). EARSS Annual Report 2005. Bilthoven: RIVM. Available at: http://www.earss.rivm.nl.
GALANI, I., SOULI, M., KORATZANIS, E., KORATZANIS, G., CHRYSSOULI, Z., GIAMARELLOU, H. (2007). Emerging bacterial pathogens: Escherichia coli, Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring the same transferable plasmid coding for metallo-β-lactamase VIM-1 in Greece. J Antimicrob Chemother. 25.
GALES, A.C., JONES, R.N., SADER, H.S. (2006). Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 12 (4), 315-321.
GIAKKOUPI, P., XANTHAKI, A., KANELOPOULOU, M., VLAHAKI, A., MIRIAGOU, V., KONTOU, S., PAPAFRAGGAS, E., MALAMOU-LADA, H., TZOUVELEKIS, L.S., LEGAKIS, N.J., VATOPOULOS, A.C. (2003). VIM-1 Metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol. 41 (8): 3893-3896.
HOOPER, D.C. (2003). Mechanisms of Quinolone Resistance. In: Hooper, D.C., Rubinstein, E., eds. Quinolone antimicrobial agents. 3th edn. Washington, DC: ASM Press, p. 41-67.
IKONOMIDIS, A., TOKATLIDOU, D., TRISTO, I., SOFIANOU, D., TSAKRIS, A., MANTZANA, P., POURNARAS, S., MANIATIS, A.N. (2005). Outbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a bla VIM-1 metallo-β-lactamase gene. J Clin Microbiol. 43 (10): 5344-5347.
JONES, M.E., DRAGHI, D.C., THORNSBERRY, C., KARLOWSKY, J.A., SAHM, D.F., WENZEL, R.P. (2004). Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob. 3: 14-24.
LEPPER, P.M., GRUSA, E., REICHL, H., HOGEL, J., TRAUTMANN, M. (2002). Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 46 (9), 2920-2925.
LIVERMORE, D.M. (1995). β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 8 (4), 557-584.
LIVERMORE, D.M. (2001). Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother. 47 (3), 247-250.
LIVERMORE, D.M. (2002). Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 34 (5), 634-640.
LIVERMORE, D.M., CANTON, R., GNIADKOWSKI, M., NORDMANN, P., ROSSOLINI, G.M., ARLET, G., AYALA, J., COQUE, T.M., KERN-ZDANOWICZ, I., LUZZARO, F., POIREL, L., WOODFORD, N. (2007). CTX-M: chang ing the face of ESBLs in Europe. J Antimicrob Chemother. 59 (2), 165-174.
OBRITSCH, M.D., FISH, D.N., MACLAREN, R., JUNG, R. (2004). National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 48 (12), 4606-4610.
PARK, C.H., ROBICSEK, A., JACOBY, G.A., SAHM, D., HOOPER, D.C. (2006). Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother. 50 (11), 3953-3955.
PIER, G.B., RAMPHAL, R. (2005). Pseudomonas aeruginosa. In: Mandell, G.L., Bennett, J.E., Dolin, R., eds. Principles and Practice of Infectious Diseases. 6th edn. Philadelphia, PA: Churchill Livingstone, 2587-2614.
POIREL, L., MENUTEAU, O., AGOLI, N., CATTOEN, C., NORDMANN, P. (2003). Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol. 41 (8), 3542-3547.
POIREL, L., NORDMANN, P. (2006). Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 12 (9), 826-836.
ROBICSEK, A., JACOBY, G.A., HOOPER, D.C. (2006). The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 6(10), 629-640.
RONALD, A. (2002). The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 113 (Suppl. 1A), 14-19.
ROSSOLINI, G.M., DOCQUIER, J.D. (2006). New β-lactamases: a paradigm for the rapid response of bacterial evolution in the clinical setting. Fut Microbiol. 1 (3), 295-308.
ROSSOLINI, G.M., MANTENGOLI, E. (2005). Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect. 11 (Suppl 4), 17-32.
SCHWABER, M.J., CARMELI, Y. (2006). Antimicrobial resistance and patient outcomes: the hazards of adjustment. Crit Care. 10 (5), 164.
STYERS, D., SHEEHAN, D.J., HOGAN, P., SAHM, D.F. (2006). Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob. 5, 2.
URBAN, C., SEGAL-MAURER, S., RAHAL, J.J. (2003). Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis. 36 (10), 1268-1274.
VAN LOOVEREN, M., GOOSSENS, H.; ARPAC Steering Group. (2004). Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect. 10 (8), 684-704.
WALSH, T.R., TOLEMAN, M.A., POIREL, L., NORDMANN, P. (2005). Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev. 18 (2), 306-325.
YAN, J.J., HSUEH, P.R., LU, J.J., CHANG, F.Y., SHYR, J.M., WAN, J.H., LIU, Y.C., CHUANG, Y.C., YANG, Y.C., TSAO, S.M., WU, H.H., WANG, L.S., LIN, T.P., WU, H.M., CHEN, H.M., WU, J.J. (2006). Extended-spectrum β-lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan. Antimicrob Agents Chemother. 50 (5): 1861-1864.
